NZ729564A - A2a antagonists as cognition and motor function enhancers - Google Patents

A2a antagonists as cognition and motor function enhancers

Info

Publication number
NZ729564A
NZ729564A NZ729564A NZ72956411A NZ729564A NZ 729564 A NZ729564 A NZ 729564A NZ 729564 A NZ729564 A NZ 729564A NZ 72956411 A NZ72956411 A NZ 72956411A NZ 729564 A NZ729564 A NZ 729564A
Authority
NZ
New Zealand
Prior art keywords
cognition
motor function
antagonists
adenosine
antagonist
Prior art date
Application number
NZ729564A
Inventor
Stephen Bandak
Kevin Black
Meghan Campbell
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/055681 external-priority patent/WO2012060844A1/en
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Priority to NZ746118A priority Critical patent/NZ746118A/en
Publication of NZ729564A publication Critical patent/NZ729564A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinson’s disease by administering an effective amount of an Adenosine 2a antagonist such as 4-hydroxy-4-methylpiperidine-1-carboxylic acid-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide (TOZADENANT, SYN115). The Adenosine 2a antagonist can optionally be administered in combination with a dopamine precursor, such as levodopa, or a dopamine receptor agonist.
NZ729564A 2010-11-05 2011-11-04 A2a antagonists as cognition and motor function enhancers NZ729564A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ746118A NZ746118A (en) 2010-11-05 2011-11-04 A2a antagonists as cognition and motor function enhancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/055681 WO2012060844A1 (en) 2010-11-05 2010-11-05 A2a antagonists as cognition and motor function enhancers
NZ71087611 2011-11-04

Publications (1)

Publication Number Publication Date
NZ729564A true NZ729564A (en) 2018-09-28

Family

ID=66476976

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ729564A NZ729564A (en) 2010-11-05 2011-11-04 A2a antagonists as cognition and motor function enhancers

Country Status (1)

Country Link
NZ (1) NZ729564A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653699B2 (en) 2015-06-19 2020-05-19 Biotie Therapies, Inc. Controlled-release tozadenant formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653699B2 (en) 2015-06-19 2020-05-19 Biotie Therapies, Inc. Controlled-release tozadenant formulations

Similar Documents

Publication Publication Date Title
NZ746118A (en) A2a antagonists as cognition and motor function enhancers
MY162895A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
BR112012020273A2 (en) PYRAZOLOPYRIDINE COMPOUNDS, PIRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE AS MGLUR4 ALLOSTERIC POINTENTIALIZERS, COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DYSFUNCTION
AR098741A1 (en) DUAL AGONISTS OF THE GLP-1 RECEIVER (PEPTIDE SIMILAR TO GLUCAGON 1) / GLUCAGÓN
MX2011008450A (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof.
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EA201270467A1 (en) POLYCYCLIC CONNECTIONS AS ANTAGONISTS OF LYSOPHOSPHATID ACID RECEPTORS
TN2011000160A1 (en) Combination of an insulin and a glp -1 agonist
EA201001253A1 (en) N, N-DESIGNED AMINOALKYLBIPHENYLES AS ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D
IN2012DN02735A (en)
IN2012DN00754A (en)
TN2011000040A1 (en) Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
MX2010004281A (en) Compositions and methods for treatment of diabetic retinopathy.
CR11849A (en) MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
EA201290266A1 (en) ANTAGONIST COMBINATIONS OF MUSCARIN RECEPTORS AND BETA-2 ADRENORECEPTOR AGONIST
HU0800434D0 (en) Template to determine the places of the injections, especially for regular medicament injection and/or blood testing
EA201270264A1 (en) Treatment of metastases in the brain
MX348933B (en) Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound.
CY1119560T1 (en) METHODS TO REDUCE ADOPTIVE DISORDER OR MENTAL HEALTH
EA201001162A1 (en) METHODS OF TREATMENT OF DISORDERS WITH REDUCTION OF BONE MASS USING AN ANTAGONIST GM-CSF
NZ598247A (en) Compositions and methods for treating parkinson’s disease
NZ729564A (en) A2a antagonists as cognition and motor function enhancers
MX2014014813A (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders.
MX2019009243A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 04 NOV 2021 BY AJ PARK

Effective date: 20190426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2022 BY CPA GLOBAL

Effective date: 20210924

LAPS Patent lapsed